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The only known filovirus, which presumably is not pathogenic for humans, is Ebola virus (EBOV) Reston. When EBOV Reston and the
highly pathogenic EBOV Zaire were grown in cell culture, comparison of the replication kinetics showed a clear growth impairment of
EBOV Reston, indicating that the replication cycle of EBOV Reston might be delayed. In addition, the cytopathic effect caused by the virus
was much milder with EBOV Reston than with EBOV Zaire. To compare replication and transcription of EBOV Reston and Zaire, a
reconstituted minigenomic replication and transcription system based on reverse genetics has been established for EBOV Reston. This system
was used to exchange the EBOV Zaire and EBOV Reston nucleocapsid (NC) proteins NP, VP35, VP30, and L, which catalyze replication
and transcription. Furthermore, chimeric minigenomes were constructed containing the cis-acting replication signals of EBOV Zaire
combined with those of EBOV Reston. Surprisingly, the cis-acting signals as well as almost all NC proteins could be exchanged between
EBOV Reston and Zaire, suggesting a high degree of functional homology of the replication/transcription complexes of EBOV Zaire and
EBOV Reston. Only the combination of EBOV Zaire VP35 and EBOV Reston L did not result in replication and transcription activity.
Although these two proteins did not constitute an active polymerase complex, it was shown by immunofluorescence analysis that they were
still able to interact.
D 2004 Elsevier Inc. All rights reserved.
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Ebola viruses (EBOV) are subdivided into four species.
Three of these species, EBOV Zaire (EBOV-Z), Sudan, and
Ivory Coast, are originated from Africa whereas the fourth
subtype, EBOV Reston (EBOV-R), is the only filovirus
originated from Asia. EBOV-R was first isolated in 1989/
1990 from Cynomolgus monkeys imported from the
Philippines to the United States (Geisbert et al., 1992;
Jahrling et al., 1990). In 1992 and 1996, respectively,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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States. These cases of EBOV-R-infected monkeys could be
traced back to Philippine export facilities (Rollin et al.,
1999). All African EBOV subtypes cause a severe
hemorrhagic disease in humans and nonhuman primates
with extraordinarily high fatality rates. Although EBOV-R
also induces hemorrhagic fever in monkeys, it seems to be
less pathogenic than the African filoviruses. Comparative
studies with monkeys experimentally infected with the
different EBOV subtypes revealed that the time course of
the disease was delayed and the number of survivors was
higher with EBOV-R infection (Fisher-Hoch and McCor-
mick, 1999). In order to investigate the role of the type I
interferon response in filovirus-infected mice, Bray (2001)
infected immunocompetent adult mice and knockout mice
lacking the interferon-a/h receptor with different Marburg05) 406–417
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petent mice survived the infection, the knockout mice were
killed by most filoviruses but not by EBOV-R, a finding
which again underlines the reduced virulence of this viral
subtype. As of today, no human disease is associated with
EBOV-R. Moreover, accidental human infections during the
outbreak in 1989/1990 were all asymptomatic (Miranda et
al., 1991). This observation suggests that EBOV-R is not
only less virulent than the African filoviruses but possibly
nonpathogenic for humans.
Due to their genome organization, filoviruses are
grouped in the order Mononegavirales. The EBOV-R
genome consists of a single-stranded nonsegmented neg-
ative-sense RNA molecule, which is about 19 kb in length
with a coding capacity for seven structural proteins (Groseth
et al., 2002; Ikegami et al., 2001). For EBOV-Z and the
closely related MBGV, it has been shown that four viral
proteins, namely NP, VP35, VP30, and L, are associated
with the viral genome and form the nucleocapsid complex
(Becker et al., 1998; Elliott et al., 1985). The nucleocapsid
proteins play a dual role in the viral replication cycle: they
are structural components of the nucleocapsid complex and
therefore involved in virus morphogenesis. Functionally,
they catalyze replication and transcription of the RNA
genome. In a reconstituted replication/transcription system,
MBGV replication and transcription was mediated by NP,
VP35, and L (Mu¨hlberger et al., 1998). In the case of
EBOV-Z, replication was supported by the same three
proteins; however, transcription was strongly dependent on
the fourth nucleocapsid protein VP30 (Mu¨hlberger et al.,
1999; Volchkov et al., 2001). Recently, it has been shown
that EBOV-Z VP30 acts as a transcription antitermination
factor immediately after transcription initiation while tran-
scription elongation is not affected by the protein (Modrof et
al., 2002, 2003; Weik et al., 2002). The function of MBGV
VP30 has not been determined yet. The nucleoprotein NP
encapsidates the viral RNA and is the driving force for
nucleocapsid formation (Kolesnikova et al., 2000; Mavrakis
et al., 2002). VP35 is homologous to the phosphoprotein P
of other Mononegavirales and together with the L protein
constitutes the polymerase complex (Mu¨hlberger et al.,
1998, 1999). EBOV-Z VP35 has been shown to act as a type
I interferon antagonist (Basler et al., 2000). Interestingly, the
protein VP35, from the less pathogenic EBOV-R, is also
able to inhibit the type I interferon immune response (Basler
et al., 2003). Amino acid sequence comparison of EBOV-R
and EBOV-Z proteins revealed a degree of homology
ranging from 58% identity for the glycoprotein (GP) to up
to 80% for VP24 (Groseth et al., 2002; Ikegami et al., 2001).
The degree of homology of NP, VP35, and VP30,
respectively, ranges from 67.6% to 68.8% identity. The L
protein is one of the best conserved EBOV proteins with
74.8% identity. The genomic ends contain important cis-
acting signals for encapsidation, replication, and transcrip-
tion initiation and are also highly conserved between
EBOV-Z and EBOV-R. Thus, the first and the last 55nucleotides of both genomes show a sequence identity of
87% and 75%, respectively.
In order to compare the replication and transcription
strategy of EBOV-R and EBOV-Z, a reconstituted repli-
cation/transcription system was established for EBOV-R.
This system will be a useful tool to investigate whether the
lower virulence of EBOV-R is due to a delay of the
replication and transcription processes.Results
Replication kinetics of EBOV-Z and EBOV-R in cell culture
First, TCID50 assays were performed to determine the
titer of EBOV-Z and EBOV-R virus stocks, respectively.
Therefore, 10-fold dilutions of the virus stocks were used to
infect vero cells, and infection of the cells was analyzed
visually every second day up to day 14 postinfection (pi).
The determined peak TCID50 titer of the EBOV-Z stock
(108 TCID50/ml) was about 100-fold higher than that of the
EBOV-R stock. In addition, the cytopathic effect caused by
the virus infection was much milder with EBOV-R than
with EBOV-Z, confirming the reduced cytopathogenicity of
EBOV-R (Fig. 1A). To compare the replication kinetics of
EBOV-Z and EBOV-R in cell culture, vero cells were
infected with either EBOV-Z or EBOV-R at a multiplicity of
infection (MOI) of 0.01. Virus growth was examined from
days 1 to 7 pi by indirect immunofluorescence staining
using virus-specific antibodies. The relative percentage of
infected cells was determined by counting fluorescent cells.
In Fig. 1B, a clear growth impairment of EBOV-R is shown
in comparison to EBOV-Z, indicating that indeed the
replication cycle of EBOV-R might be delayed.
Development of a reconstituted replication and
transcription system for EBOV Reston
In order to compare the replication/transcription strat-
egies of EBOV-R and EBOV-Z, a reconstituted replication
and transcription system for EBOV-R was established. First,
the sequence of the used virus isolate EBOV-R Pennsylva-
nia, 1989, was determined (GenBank accession number:
AY769362). Subsequently, the genes coding for the
nucleocapsid proteins NP, VP35, VP30, and L were
amplified by RT-PCR and inserted into the expression
vector pTM1 under the control of a T7 RNA polymerase
promoter. Mutations within the cloned genes were removed
by in vitro mutagenesis. As template for the nucleocapsid
proteins, an EBOV-R-specific minigenome was designed
containing the 3Vand 5Vends of the viral genome flanking
the CAT gene as a reporter gene (Fig. 2). These genetic
elements were cloned into the vector 2,0 (kindly provided
by A. Ball, Department of Microbiology, University of
Alabama at Birmingham, Birmingham, AL, USA) between
the T7 RNA polymerase promoter and the hepatitis delta
Fig. 1. Replication kinetics of EBOV-Z and EBOV-R. (A) Cytopathic effects caused by EBOV-Z and EBOV-R. Vero cells were infected with either EBOV-Z or
EBOV-R at an MOI of 0.1. At 4 days pi, cells were examined by light microscopy. (B) Comparison of infectivity of EBOV-Z and EBOV-R. Vero cells were
infected with either EBOV-Z or EBOV-R at an MOI of 0.01. Up to day 7 pi, cells were harvested daily and subjected to indirect immunofluorescence analysis
by using antibodies directed against EBOV-Z NP or EBOV-R NP, respectively. In addition, cell nuclei were stained with DAPI. Infectivity of the viruses was
determined by counting fluorescent cells.
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plasmid resulted in the negative-sense minigenomic RNA
3R–5R with exact 5V and 3V ends. To test whether the
nucleocapsid proteins and the minigenome were functional,
BSR T7/5 cells (Buchholz et al., 1999) constitutively
expressing the T7 RNA polymerase were transfected with
the plasmids coding for NP, VP35, VP30, L, and 3R–5R. At
2 days posttransfection, the cells were lysed and CAT
activity was determined. In Fig. 3, it is shown that four
nucleocapsid proteins were essential to support replicationFig. 2. Sketch of the EBOV-R-specific minigenomes 3R–5R and 3R–5RD248. Th
vector 2,0 (gray bar) in negative orientation under the control of the T7 RNA
nucleotides 1–466, the 5Vend nucleotides 18192–18895. Minigenome 3R–5RD248
delta ribozyme sequence is located downstream of the leader. As a reporter gen
sequences. Transcription with T7 RNA polymerase resulted in the synthesis
autocleavage of the ribozyme. Used restriction sites are indicated by arrows. TC
translation start site of the EBOV-R NP gene; TC stop L: transcription stop site of
isolate Pennsylvania, 1989 (GenBank accession number: AY769362).and transcription. In the absence of the fourth nucleocapsid
protein, VP30, no CAT activity could be detected, indicating
that EBOV-R VP30 serves as a transcription activator
similarly to EBOV-Z VP30.
Previous observations with the MBGV and EBOV-Z
minigenome systems revealed that the relative and absolute
amounts of the different plasmids used for transfection
were critical for replication and transcription efficiency
(Mu¨hlberger et al., 1998, 1999). Thus, the EBOV-R-specific
plasmids were titrated (Fig. 4A). While the optimal amounte 3Vand 5Vends of the EBOV-R genome (white bars) were cloned into the
polymerase promoter (T7). The 3Vend of minigenome 3R–5R comprises
contains a truncated 3Vregion comprising nucleotides 1–248. The hepatitis
e, the CAT gene (black bar) was inserted between the EBOV-R-specific
of negative strand minigenomes. Exact 3V ends were then generated by
start NP: transcription start site of the EBOV-R NP gene; TL start NP:
the EBOV-R L gene. Numbers refer to the genomic sequence of EBOV-R,
Fig. 3. Reporter gene expression mediated by EBOV-R nucleocapsid
proteins. BSR T7/5 cells were transfected with plasmids coding for the
EBOV-R minigenome 3R–5R and the nucleocapsid proteins NP, VP35,
VP30, and L as indicated in the figure. At 2 days posttransfection, cells
were harvested and CAT activity was determined.
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the system was much less tolerant towards the plasmids
encoding VP30 and VP35, with DNA amounts peaking at
0.5 and 0.1 Ag input DNA, respectively. The results of the
first titration experiments were used to carry out a second
round of titration so as to optimize the amount of plasmid
DNA used (Fig. 4B). For the subsequent experiments, the
following amounts of plasmid DNA were used: 1 Ag pT/
NPRES, 0.5 Ag pT/VP35RES, 0.5 Ag pT/VP30RES, 2 Ag pT/
LRES, and 2 Ag 3R–5R.
EBOV-R VP30 serves as a transcription activator
To confirm the finding that EBOV-R VP30 might
function as a transcription activator, replicated and tran-
scribed RNA species were detected using Northern blot
analysis. Discrimination of the RNA species was performed
by nuclease treatment and oligo(dT) binding. Transcribed
viral mRNA is polyadenylated and binds to oligo(dT)
cellulose. Furthermore, the transcribed RNA species are not
encapsidated and can be degraded by nucleases. In contrast
to the polyadenylated transcribed RNA, replicated RNA is
not polyadenylated but is tightly encapsidated by the
nucleocapsid proteins and therefore nuclease resistant. To
isolate mRNA, BSR T7/5 cells were transfected with
plasmids coding for the nucleocapsid proteins and the
minigenome. At 2 days posttransfection, cellular RNA was
isolated, purified by oligo(dT) cellulose binding, and
subjected to Northern hybridization. When BSR T7/5 cells
were used for isolation of replicated RNA, the background
staining in the Northern hybridization was very high. To
avoid this problem, Huh-T7 cells were transfected with the
EBOV-R-specific plasmids. Constitutive expression of the
T7 RNA polymerase in Huh-T7 cells is less efficient than in
BSR T7/5 cells. In order to boost expression of the T7 RNA
polymerase, Huh-T7 cells were cotransfected with the
plasmid pC-T7Pol encoding the T7 RNA polymerase.Because Huh-T7 cells are more sensitive to the addition
of the reagent FUGENE6 than BSR T7/5 cells, the amount
of FUGENE6 and consequently the amount of input DNA
were slightly reduced as indicated in the legend of Fig. 5A.
At 2 days posttransfection, cells were lysed and the lysates
were treated with micrococcal nuclease prior to RNA
purification. The purified RNA samples were analyzed by
Northern hybridization using a negative-sense-orientated
probe directed against the CAT gene to detect positive-sense
minigenome RNA representing a replicative intermediate
and mRNA. As a control, in vitro transcribed positive-sense
3E–5E minigenomic RNA was used (Fig. 5A, lane 1). The
upper band shown in lane 1 represents the uncleaved
transcript consisting of the minigenome and the ribozyme
whereas the lower band corresponds to the processed
minigenome after autocleavage of the ribozyme. Fig. 5A
shows that three nucleocapsid proteins, NP, VP35, and L,
were sufficient to support replication. In addition to
minigenome 3R–5R, minigenome 3R–5RD248, which con-
tains only 248 nucleotides of the 3V end, was used as a
template (Fig. 2). Interestingly, this minigenome was as
efficiently replicated as minigenome 3R–5R, indicating that
the first 248 nucleotides of the EBOV-R genome are
sufficient to support replication (Fig. 5A). In contrast,
transcription was strongly dependent on the presence of the
fourth nucleocapsid protein, VP30 (Fig. 5B). Thus, the
results of the Northern blot assays confirmed that EBOV-R
VP30 acts as a transcription activation protein. The
observed difference in size of the EBOV-Z and EBOV-R
mRNAs is due to the different localization of the tran-
scription stop signal of the L gene within the respective
genome. The transcription stop signal of the EBOV-Z L
gene is located only 66 nucleotides downstream of the ORF,
and that of the EBOV-R L gene 691 nucleotides down-
stream of the ORF. Interestingly, the amount of detected
mRNA was lower for the EBOV-R system compared to
EBOV-Z, suggesting that transcription and/or replication
occurred less efficiently. However, it cannot be ruled out
that the smaller amount of transcribed EBOV-R mRNA is
due to other possibilities, such as differences in T7 RNA
polymerase efficiency, encapsidation, or mRNA stability.
Exchange of the nucleocapsid proteins between EBOV-R
and EBOV-Z
Perhaps, due to the close relationship of EBOV-Z and
EBOV-R, it might be possible to exchange the respective
nucleocapsid proteins and the minigenomes. To this end,
BSR T7/5 cells were transfected with all possible combina-
tions of EBOV-Z and EBOV-R nucleocapsid protein genes
and with either the EBOV-Z minigenome 3E–5E or the
EBOV-R minigenome 3R–5R. Fig. 6A shows that it is
indeed possible to exchange the EBOV-Z nucleocapsid
proteins with those of EBOV-R when the 3E–5E mini-
genome was used with one exception: the combination of
EBO-Z VP35 and EBOV-R L did not work at all (Fig. 6A,
Fig. 4. Optimization of the reconstituted EBOV-R replication system by plasmid titration. BSR T7/5 cells were transfected with varying amounts of plasmids
coding for the EBOV-R minigenome 3R–5R and the nucleocapsid proteins NP, VP35, VP35, and L. At 2 days posttransfection, cells were probed for CAT
activity and acetylated chloramphenicol was quantified. (A) The first titration experiments were performed with set amounts of four of the plasmids (0.5 Ag of
pT/NPRES, 0.5 Ag of pT/VP35RES, 0.5 Ag pT/VP30RES, 1 Ag of pT/LRES, and 2 Ag of 3R–5R) and various amounts of the titrated plasmid as indicated in the
figure. (B) Second round of plasmid titration based on the results shown in A. The amount of the different plasmids is indicated underneath the graph. The CAT
assay is not in a linear range when the diacetylated form is synthesized. This was the case when values of more than 90% acetylation were achieved. Thus, the
data shown here represent a qualitative rather than an exact quantitative comparison demonstrating clear differences in the replication/transcription efficiency of
the different samples.
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combinations resulted in CAT activity, however, the more
EBOV-Z-specific plasmids were exchanged with those of
EBOV-R, the less CAT activity was measured. Similar
results were obtained when the EBOV-R-specific nucleo-
capsid protein genes were exchanged with those of EBOV-Z
when minigenome 3R–5R was used (Fig. 6B). Again, the
combination of EBOV-Z VP35 and EBOV-R L did not
result in CAT activity (Fig. 6B, lanes 4, 7, 10, and 13),
indicating that these two proteins are not able to constitute
an active polymerase complex. In addition, the combination
of EBOV-R NP and EBOV-Z L seemed to be largely
nonfunctional in the EBOV-R minireplicon system (Fig. 6B,lanes 6, 11, 12, and 16). Taken together, these results
suggest a distinct functional and structural similarity of
EBOV-R and EBOV-Z nucleocapsid proteins. Exchange of
the EBOV-R nucleocapsid proteins with those of MBGV,
however, did not result in any transcription activity (data not
shown).
EBOV-Z VP35 and EBOV-R L do not constitute an active
polymerase complex but interact
In order to analyze whether the lack of function of
EBOV-Z VP35 and EBOV-R L as polymerase complex
might be due to the incapability of both proteins to interact,
Fig. 6. Exchange of EBOV-Z and EBOV-R nucleocapsid proteins. BSR
T7/5 cells were transfected with plasmids coding for EBOV-Z and EBOV-
R nucleocapsid proteins, respectively, and with the plasmid encoding the
respective minigenome. At 2 days posttransfection, cells were lysed and
CAT activity was determined. (A) Exchange of EBOV-Z nucleocapsid
proteins by EBOV-R nucleocapsid proteins. Cells were transfected with
plasmids coding for the minigenome 3E–5E and EBOV-Z nucleocapsid
proteins (lanes 1 and 2). The amount of used EBOV-Z plasmid DNA is
given in the legend to Fig. 5. In the following lanes, one, two, three, or all
nucleocapsid proteins were exchanged by the respective EBOV-R
homologous proteins. The amount of the respective EBOV-R plasmid
DNA used for transfection is given in the legend to Fig. 4. (B) Exchange
of EBOV-R nucleocapsid proteins by EBOV-Z nucleocapsid proteins.
Cells were transfected with plasmids coding for the minigenome 3R–5R
and EBOV-R nucleocapsid proteins (lanes 1 and 2). In the following
lanes, one, two, three, or all nucleocapsid proteins were exchanged by the
respective EBOV-Z counterpart. Refer to the Fig. 4, legend, for a des-
cription of the quantification of the CAT assay.
Fig. 5. Detection of replicated and transcribed RNA species. (A) Huh-T7
cells were transfected with plasmids encoding the EBOV-R nucleocapsid
proteins (0.7 Ag of pT/NPRES, 0.35 Ag of pT/VP35RES, and 1.5 Ag of
pT/LRES) and either minigenome 3R–5R or minigenome 3R–5RD248 (1 Ag
each) as indicated in the figure. In addition, cells were transfected with
0.5 Ag pC-T7Pol. At 2 days posttransfection, cells were lysed and treated
with micrococcal nuclease. Subsequently, protected RNAwas purified, sub-
jected to Northern blot analysis, and detected by using a negative-sense
RNA probe binding to the CAT gene. (B) BSR T7/5 cells were either trans-
fected with plasmids coding for the EBOV-Z minigenome system (0.5 Ag of
pT/NPEBO, 0.5 Ag of pT/VP35EBO, 0.1 Ag pT/VP30EBO, 1 Ag of pT/LEBO,
and 1 Ag of 3E–5E) or with plasmids coding for the EBOV-R minigenome
system. At 2 days posttransfection, cells were lysed, total cellular RNAwas
isolated, and mRNA species were extracted by oligo(dT) cellulose. Eluted
mRNAs were subjected to Northern blot analysis as described above.
Specific mRNA bands are marked by arrowheads. As a control, in vitro
transcribed positive-sense 3E–5E minigenomic RNA was used.
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related MBGV, it has been shown previously that VP35
interacts with L. Also, trimeric complexes consisting of NP,
VP35, and L have been identified indicating that VP35
directs L to the NP-encapsidated RNA genomes by acting as
a linker protein between NP and L (Becker et al., 1998).
When filoviral NP is expressed in the absence of other viral
proteins, it forms characteristic inclusion bodies that contain
highly ordered tubular structures resembling the nucleocap-
sids in virus-infected cells (Kolesnikova et al., 2000). In
contrast, the other nucleocapsid proteins are more or less
homogeneously distributed in the cytoplasm when solely
expressed in cells. In cells transfected with MBGV NP and
VP35 genes, coexpression of NP and VP35 led to
relocalization of VP35 in NP-derived inclusion bodies.
When MBGV NP, VP35, and L are coexpressed, L is also
directed into NP-derived inclusions (Becker et al., 1998).
Because EBOV-Z NP and VP35 are also found to be
localized in inclusion bodies in EBOV-Z-infected cells
(Bjorndal et al., 2003), it is possible that EBOV NP, VP35,
and L would interact similarly to MBGV proteins. To
investigate if EBOV-Z VP35 and EBOV-R L do interact,
immunofluorescence analyses were performed. To this end,
HeLa cells were infected with MVA-T7 and subsequently
transfected with plasmids coding for the NP, VP35, and L
proteins of EBOV-Z and EBOV-R in different combina-
tions. Because no antibodies directed against the L proteins
are available, all L constructs were tagged by a FLAG
epitope. First, it was confirmed that the typical inclusionbodies were formed when NP and VP35 were coexpressed
in the absence of L (Fig. 7F). Subsequently, it is shown that
the L proteins of EBOV-Z and EBOV-R are homogeneously
distributed in the cytoplasm of infected and transfected cells
when expressed in the absence of other filoviral proteins
(Fig. 7A). Coexpression of autologous NP and VP35 with L
Fig. 7. Immunofluorescence analysis to investigate binding of L to VP35. HeLa cells grown on glass cover slips were infected with MVA-T7 and 1 h pi
transfected with various combinations of plasmids coding for EBOV-Z and EBOV-R NP, VP35, and LFlag. Because no antibodies directed against the L
proteins are available, the EBOV-Z and EBOV-R L proteins were tagged by the FLAG epitope. In addition to the full-length EBOV-R L, the truncated protein
EBOV-R LFlag-879 comprising the aminoterminal part of the protein up to amino acid 879 was used. At 8–12 h posttransfection, cells were fixed, permeabilized,
and subjected to immunofluorescence analysis. The FLAG-tagged EBOV-Z and EBOV-R L proteins were visualized by using a monoclonal anti-FLAG
antibody (a-FLAG). EBOV-Z and EBOV-R NP were each stained with a specific monoclonal antibody (a-NPZ, a-NPR). Bound antibodies were detected with
FITC- or rhodamine-conjugated goat anti-mouse IgG antibodies. (A) Solely expressed EBOV-R LFlag (LR), EBOV-R LFlag-879 (LR-879), or EBOV-Z LFlag (LZ),
respectively; (B) coexpression of L with autologous NP and VP35; (C) coexpression of L with heterologous NP and VP35; (D) coexpression of EBOV-R NP
(NPR) with VP35 (VP35R) and EBOV-Z NP (NPZ) with VP35 (VP35Z), respectively, stained with an anti-FLAG antibody; (E) mock- and MVA-T7-infected
cells stained with an anti-FLAG antibody; (F) coexpression of NPR and VP35R stained with an anti-NPR antibody and coexpression of NPZ and VP35Z stained
with an anti-NPZ antibody.
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(Fig. 7B). Interestingly, an EBOV-R-specific truncated L
protein comprising the first 879 amino acids of L (L879) also
relocalized into the NP-derived inclusions, indicating that
the N-terminal region of EBOV-R L is sufficient for
interaction with VP35. When EBOV-R L, EBOV-R L879,
and EBOV-Z L, respectively, were coexpressed with
heterologous NP and VP35, the L proteins were detected
in NP-derived inclusions, suggesting that complex forma-
tion took place in each case (Fig. 7C). These data indicate
that although EBOV-Z VP35 and EBOV-R L are able to
interact, the formed complex is not functional.
Chimeric minigenomes
In Figs. 6A (lanes 17) and 6B (lane 17), it was shown
that the replication and transcription promoter sequences of
EBOV-Z were accepted by EBOV-R and vice versa. It was
now of interest to investigate whether chimeric minige-
nomes whose 3Vor 5Vends were replaced by the respective
3Vor 5Vregions of the heterologous virus were accepted as
templates for replication and transcription. Fig. 8 shows that
the chimeric minigenomes were efficiently replicated and
transcribed by both polymerase complexes, indicating that
the 3V and 5V promoter regions of EBOV-R and EBOV-Z
show a high degree of structural similarity. Again, the
replication/transcription efficiency of the different minige-
nomes was always lower in the EBOV-R replication system.Discussion
In the present study, we have developed a reconstituted
minireplicon system for EBOV-R. We showed that three out
of the four nucleocapsid proteins were sufficient to support
EBOV-R replication, whereas for transcription, the fourth
nucleocapsid protein VP30 was also needed. These data
indicate that the replication and transcription strategy ofFig. 8. Transcription and replication of chimeric minigenomes. BSR T7/5
cells were transfected with plasmids coding either for EBOV-Z (Z) or
EBOV-R (R) nucleocapsid proteins NP, VP35, VP30, and L. In lanes 6 and
8, the plasmid coding for the respective L protein was omitted. Cells
additionally were transfected with the respective minigenome as indicated
in the figure. Two days later, cells were assayed for CAT activity.EBOV-R is similar to that of EBOV-Z, thus the same
proteins are required for replication and transcription
(Mqhlberger et al., 1999, 2002; Volchkov et al., 2001;
Watanabe et al., 2004). In contrast, transcription of MBGV
minigenomes occurs independently of VP30 (Mqhlberger et
al., 1998). It has been shown for EBOV-Z that VP30-
dependent transcription is regulated by an RNA secondary
structure formed by the transcription start signal of NP gene
and downstream sequences (Weik et al., 2002). While the
NP gene transcription start sites of EBOV-R and EBOV-Z
are identical, there are two nucleotide exchanges within the
downstream located sequences involved in stem-loop
structure formation. Interestingly, these two nucleotides
are located within the loop whereas the nucleotides involved
in base pairing are conserved between EBOV-R and EBOV-
Z, thus leading to formation of similar RNA structures.
EBOV-Z VP30 is a zinc binding protein. Destruction of the
zinc binding domain leads to a loss of function of the
protein as transcription activator (Modrof et al., 2003). This
VP30-specific zinc binding domain is well conserved
between EBOV-Z and EBOV-R, suggesting that EBOV-Z
and EBOV-R transcription processes might be regulated by
the same mechanism.
Titration experiments performed with the plasmids
encoding the EBOV-R nucleocapsid proteins revealed
optimal amounts for NP, VP35, VP30, and L leading to
maximal CAT activity. When the amount of input DNAwas
further increased, CAT activity declined, suggesting that
overexpression of one nucleocapsid protein gene led to an
imbalance between the different components of the repli-
cation complex. Similar findings were obtained concerning
the NP, VP35, and VP30 plasmid DNA of EBOV-Z;
however, the total amount of each EBOV-Z input DNA
needed for maximal CAT activity was different compared to
the EBOV-R system (Mqhlberger et al., 1999). While large
amounts of EBOV-Z L input DNA were tolerated in the
EBOV-Z system without suppressing reporter gene activity
(Mqhlberger et al., 1999), increasing amounts of EBO-R L
input DNA above 2 Ag led to a decrease of CAT activity.
This difference might be due to different expression rates of
these proteins.
The nucleocapsid proteins of EBOV-Z and EBOV-R
show a varying degree of homology, ranging from 67.6% to
74.8% identity (Groseth et al., 2002; Ikegami et al., 2001).
The leader and the trailer regions containing the signals for
encapsidation, replication, and transcription initiation are
also highly conserved between EBOV-Z and EBOV-R. This
high degree of conservation is reflected by the fact that
EBOV-Z nucleocapsid proteins were able to rescue the
EBOV-R-specific minigenome and vice versa, thus accept-
ing the replication and transcription promoters of the
heterologous genome. Moreover, chimeric minigenomes
containing the leader of EBOV-Z in combination with the
trailer of EBOV-R and vice versa were replicated and
transcribed by both sets of nucleocapsid proteins. Interest-
ingly, the amount of CAT activity was lower with the
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tion complex of EBOV-R might function less efficiently
compared to EBOV-Z. Amino acid sequence comparison of
the nucleocapsid proteins of MBGV and Ebola viruses
revealed a degree of homology between 35% and 49%
identity only. Consequently, it was not possible to exchange
the nucleocapsid proteins of EBOV-R and MBGV. Similar
results were obtained with MBGV and EBOV-Z NP, VP35,
and L. In contrast, MBGV VP30 was able to support
EBOV-Z-specific transcription, albeit with a low efficiency
(Mqhlberger et al., 1999). It has been reported for other
members of the order Mononegavirales that they accept
heterologous minigenomic RNA derived from closely
related viruses as templates for replication and transcription.
Thus, human parainfluenza virus (PIV) types 1 and 3
supported replication of a Sendai virus minigenome,
whereas measles virus did not (Curran and Kolakofsky,
1991; Pelet et al., 1996). Yunus et al. (1999) demonstrated
that a bovine respiratory syncytial virus (RSV) minireplicon
was rescued in cells infected with human RSV and ovine
RSV, respectively, but not in bovine PIV type-3-infected
cells. It is noteworthy that the nucleocapsid proteins of
human, bovine, and ovine RSV show a very high level of
amino acid identity in the range of 80–93% (Yunus et al.,
1999). On the other hand, Dimock and Collins (1993)
observed that human PIV type 3 minigenomes were neither
rescued by human RSV nor by the very closely related
bovine PIV type 3. Taken together, these data indicate that
the replication complexes are specific for the autologous
RNA species but that occasionally very closely related
viruses have the capacity to replicate and transcribe
heterologous RNAs.
When the nucleocapsid proteins of EBOV-Z and EBOV-
R were exchanged, almost all combinations were able to
support replication and transcription; however, certain
combinations significantly reduced replication efficiency.
As for the EBOV-Z system, it seemed that the more
heterologous the proteins the less efficient the replication.
Especially, this was true for the exchange of NP: with one
exception, swapping of the NP protein led to a remarkable
decrease in CAT activity. For the EBOV-R system, it was
shown that the combination of EBOV-R NP and EBOV-Z L
dramatically diminished replication and transcription activ-
ity. These results have interesting connotations when
applied towards construction of recombinant attenuated
Ebola viruses. For a recombinant human PIV type 3 virus,
in which the NP gene was replaced by the bovine PIV type 3
counterpart, it has been demonstrated that the virus was
attenuated in primates (Bailly et al., 2000).
The only nucleocapsid combination not working at all
was the combination of EBOV-Z VP35 and EBOV-R L.
Filovirus VP35 is the equivalent of paramyxo- and
rhabdovirus P proteins and constitutes together with L the
polymerase complex (Mu¨hlberger et al., 1999). For MBGV,
it has been shown that VP35 binds to L and NP, thus
directing L into NP-derived inclusion bodies (Becker et al.,1998). Here, we have shown indirectly that EBOV-Z VP35
and EBOV-R L interaction still occurred; however, the
enzymatic function of this complex was lost.
In summary our data revealed that the replication/
transcription complexes of EBOV-Z and EBOV-R show a
high degree of functional homology. The leader and trailer
sequences are conserved and are accepted by the nucleo-
capsid proteins of the heterologous virus. In addition, it was
possible to exchange almost all EBOV-R and EBOV-Z
nucleocapsid proteins, again underlining the close relation-
ship between these viruses. It seems, however, that at least
in the minigenome systems, EBOV-R replication and
transcription is less efficient compared to EBOV-Z. Future
studies will examine if the delayed replication cycle and the
reduced virulence of EBOV-R are due to decelerated
replication and transcription processes.Materials and methods
Cell lines and viruses
Vero and HeLa cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS). Huh-T7 cells (derived from
the human hepatoblastoma cell line Huh7) constitutively
expressing the T7 RNA polymerase (kindly provided by V.
Gaussmqller, Department of Medical Molecular Biology,
University of Lqbeck, Germany) were grown in DMEM
supplemented with 10% FCS and 1 mg/ml geneticin
(Schultz et al., 1996). BSR T7/5 cells (derived from a
BHK-21 cell line), constitutively expressing the T7 RNA
polymerase (kindly provided by K. K. Conzelmann, Max
von Pettenkofer Institute and Gene Center, Munich,
Germany), were cultured as described by Buchholz et al.
(1999). The recombinant vaccinia virus MVA-T7 containing
the T7 RNA polymerase gene was grown in chicken embryo
fibroblasts (Sutter et al., 1995). EBOV-Z, strain Mayinga
and the EBOV-R isolate Pennsylvania, 1989, were propa-
gated in vero cells. For preparation of virus stocks,
supernatants were harvested at 4 days (EBOV-Z) or at 14
days pi (EBOV-R). To determine the titer of the virus stocks,
TCID50 assays were performed. Briefly, vero cells seated in
96-well plates were infected by 10-fold dilutions of EBOV-
R or EBOV-Z virus stocks, respectively, and examined for
cytopathic effects by light microscopy. The TCID50 titer of
the EBOV-Z stock was determined at 7–8 days pi and that of
the EBOV-R stock at 14 days pi. Calculation of TCID50 was
performed by the Spearman–K7rber method.
For cloning of the nucleocapsid protein genes and the
minigenome, the genomic RNA of EBOV-R was used. The
virus was propagated in vero cells, supernatants were
harvested at 10 days pi, clarified by a short centrifugation
step, mixed with an equal volume of RLT buffer of an
RNeasy kit (Qiagen), and supplied with 0.6 volume of
100% ethanol. Finally, the RNA was purified according to
Y. Boehmann et al. / Virology 332 (2005) 406–417 415the supplier’s instructions. All work with infectious EBOV-
R and EBOV-Z was performed in the BSL4 facility of the
University of Marburg.
Determination of the 3V and 5V ends of the EBOV Reston
genome and sequencing of the nucleocapsid protein genes
Determination of the 5Vends of the EBOV-R genome was
performed by using a 5VRACE kit (Invitrogen). For cDNA
synthesis, a primer was used which bound to nucleotides
18,483–18,506. Tailing of the cDNA was done with dGTP
or dCTP, respectively. The 5V end was determined after
nested PCR with the tailed cDNA as a template and
subsequent sequencing of the resulting PCR fragments. To
determine the 3Vend, the genomic RNAwas circularized by
using T4 RNA ligase (Roche). The ligated RNA was then
used as a template for RT-PCR using a primer pair binding
to nucleotides 420–443 and 18,483–18,506, respectively.
RT-PCR was followed by two nested PCRs using a primer
pair binding to nucleotides 313–338 and 18,570–18,593,
respectively, for the first nested PCR and a primer binding to
nucleotides 116–140 and 18,772–18,794, respectively, for
the second nested PCR. For sequencing of the nucleocapsid
protein genes, RT-PCR was performed with the genomic
EBOV-R RNA as template. Resulting fragments were
subcloned into the vector TOPO TA (Invitrogen) and
subjected to sequencing (GenBank accession number:
AY769362).
Cloning of the EBOV Reston nucleocapsid protein genes
and the minigenomes
To generate cDNA clones encoding the nucleocapsid
protein genes NP, VP35, VP30, and L, the EBOV-R-specific
genomic RNA was reverse transcribed with Omniscript
Reverse Transcriptase (Qiagen) and amplified via PCR with
Pwo polymerase (Roche) by using purified genomic EBOV-
R RNA as a template. The amplified genes were inserted
into the expression vector pTM1 under the control of the T7
RNA polymerase promoter. To insert additional restriction
sites, a DNA linker containing the recognition sites for SfiI,
NotI, and SacII was cloned into the BamHI site of pTM1.
The NP gene flanked by an EcoRI and a NotI site fragment
comprised nucleotides 464–2683 of the viral RNA, the
VP35 and VP30 gene fragments, respectively, were flanked
by EcoRI and XhoI sites and comprised nucleotides 3155–
4144 (VP35) and 8487–9353 (VP30), respectively. For
cloning of the L gene, which is 6636 nucleotides in length,
three fragments of about 2 kb were amplified by RT-PCR.
These fragments were ligated by using internally located
restriction sites (BstBI and NruI) and inserted in the pTM1
vector by using the flanking restriction sites XmaI and
BamHI. The generated plasmids were designated pT/NPRES,
pT/VP35RES, pT/VP30RES, and pT/LRES. Mutations within
the genes, which were introduced during cloning, were
removed by in vitro mutagenesis using the Quickchangemutagenesis PCR kit (Stratagene) according to the suppli-
er’s instructions.
Because no antibodies directed against the L proteins of
EBO-Z and EBOV-R are available, both proteins were
tagged with a FLAG epitope located at the aminoterminus
of the proteins. Construction of the FLAG-tagged L
proteins was performed by using PCR technique with
either pT/LRES or pT/LEBO (Mu¨hlberger et al., 1999) as
template. In addition, a truncated FLAG-tagged EBOV-R L
protein was constructed containing the first 879 amino
acids of the protein. The resulting plasmids were designated
pT/LRES-Flag, pT/LRES-879-Flag, and pT/LEBO-Flag.
The EBOV-R-specific minigenome 3R–5R contains the
3Vand 5Vends of the EBOV-R genome separated by the CAT
gene as reporter gene. The 3Vend comprises nucleotides 1–
466, the 5Vend nucleotides 18192–18895. As a backbone for
generation of the EBOV-R-specific minigenome 3R–5R and
the chimeric minigenomes 3R–5E and 3E–5R, the EBOV-Z-
specific minigenome 3E–5E was used (Mu¨hlberger et al.,
1999). In this minigenome, the EBOV-Z 3V end was
exchanged with the EBOV-R-specific 3V end by using the
restriction sites RsrII and NdeI, and the EBOV-Z 5Vend was
exchanged with the EBOV-R 5Vend by using the restriction
sites NotI and XmaI (Fig. 2). For generation of minigenome
3R–5RD248 containing a truncated 3V region, the 3V end of
minigenome 3R–5R was removed by digestion with NdeI
and RsrII and replaced by a PCR fragment containing
nucleotides 1–248 of the EBOV-R sequence which was
flanked by NdeI and RsrII restriction sites.
Transfection of BSR T7/5 and Huh-T7 cells
Transfection of BSR T7/5 or Huh-T7 cells (5  105 in a
7-cm2 well) was performed using FUGENE6 (Roche
Molecular Biochemicals) as described previously (Modrof
et al., 2002). The amount of plasmids used for the respective
transfection procedure is indicated in the figure legends.
Cells were harvested at 2 days posttransfection, and cell
lysates were either used for CAT assays or for RNA
analyses.
Detection of transcribed and replicated RNA
BSR T7/5 or Huh-T7 cells grown in 6-well plates were
transfected with EBOV-R-specific plasmids as described
above. When Huh-T7 cells were used, cells were transfected
additionally with 0.5 Ag of plasmid pC-T7Pol expressing
the T7 RNA polymerase (kindly provided by T. Takimoto,
St. Jude Children’s Research Hospital, Memphis, TN, USA,
and Y. Kawaoka, University of Wisconsin, Madison, WI,
USA; Neumann et al., 2002). At 2 days posttransfection,
cells were washed twice with PBS, scraped into the washing
buffer, and pelleted. For mRNA isolation, total cellular
RNA was isolated using the RNeasy kit (Qiagen) according
to the manufacturer’s instructions. Subsequently, polyade-
nylated RNA was purified by using oligo(dT) cellulose as
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replicated RNA is described elsewhere (Grosfeld et al.,
1995; Mqhlberger et al., 1999). Briefly, cell pellets were
resuspended in 200 Al micrococcal nuclease buffer (10 mM
NaCl, 10 mM Tris [pH 7.5], 10 mM MgCl2, 5% Triton X-
100, 0.3% sodium deoxycholate, 10 mM CaCl2), sheared
and sonicated for 1 min. After addition of 51 U micrococcal
nuclease (Roche Molecular Biochemicals), cell lysates were
incubated for 70 min at 33 8C. Thereafter, protected RNA
species were purified by using an RNeasy kit (Qiagen).
Finally, the replicated and transcribed RNA species were
subjected to Northern blot analysis. To detect the specific
RNA species, the negative-sense digoxygenin-labeled
riboprobe DIG-BS/CAT, which binds to the CAT gene,
was used (Mqhlberger et al., 1998).
CAT assay
BSR T7/5 cells were transfected as described above. At 2
days posttransfection, cells were washed twice with PBS
and scraped into 150 Al of reporter lysis buffer (Promega)
per well. CAT activity was determined using a standard
protocol. The amount of acetylated chloramphenicol was
quantified with a Bioimager Analyzer (Fuji BAS-1000)
using the Raytest TINA software.
Immunofluorescence analysis
Infected and transfected HeLa cells
HeLa cells grown on glass coverslips to 50% confluence
were infected with MVA-T7 at an MOI of 5. At 1 h pi, cells
were transfected by using Lipofectin (GIBCO-BRL) with
various combinations of the following plasmids: 1 Ag of
pT/LRES-Flag, pT/LRES-879-Flag, or pT/LEBO-Flag, and 0.5 Ag
of pT/NPRES, pT/VP35RES, pT/NPEBO, or pT/VP35EBO. At
8–12 h posttransfection, cells were washed three times with
PBS and fixed for 15 min at room temperature in 3%
paraformaldehyde. Thereafter, cells were treated with 0.1 M
glycine and permeabilized for 15 min with 0.1% Triton X-
100. Cells were incubated with the respective antibodies for
1 h at room temperature and then washed four times with
PBS and stained with the appropriate secondary antibodies
for 1 h at room temperature. To detect EBOV-Z NP, a
monoclonal antibody directed against EBOV-Z NP was
used (1:20 dilution). For staining of EBOV-R NP, a
monoclonal antibody directed against EBOV-R NP was
used (1:100 dilution; kindly provided by A. Sanchez,
Centers for Disease Control, Atlanta, GA USA). Staining
of the FLAG-tagged L proteins was performed with an
anti-FLAG M2 monoclonal antibody (1:200 dilution,
Sigma-Aldrich). Bound antibodies were detected with
FITC- or rhodamine-conjugated goat anti-mouse IgG anti-
bodies (1:200 dilution, Dianova). Finally, cells were
washed four times with PBS, dipped into H2O, covered
with mounting medium, and examined using a fluorescence
microscope.Infected vero cells
Vero cells seated in chamber slides were infected with
EBOV-Z and EBOV-R, respectively, at an MOI of 102. At
1–7 days pi, cells were inactivated by addition of 4%
paraformaldehyde for at least 12 h. Cells were treated with
0.1 M glycine and permeabilized for 5 min at room
temperature with 0.1% Triton X-100. Incubation with the
respective antibody was performed as described above. To
detect EBOV-Z infection, the abovementioned monoclonal
antibody directed against EBOV-Z NP was used. For
staining of EBOV-R-infected cells, the monoclonal antibody
directed against EBOV-R NP was used. Bound antibodies
were detected with a Texas red-conjugated goat anti-mouse
IgG antibody (1:200 dilution, Dianova). To visualize the
nuclei, cells were stained additionally with 0.1 Ag/ml 4V,6V-
diamidino-2-phenylindole hydrochloride (DAPI) for 5 min
at room temperature.Acknowledgments
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